Incyte reported $5.36B of revenue over the trailing twelve months, +21% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $5.36B (to Q1 2026). Net Income: $1.43B, trailing twelve months to Q1 2026. Op Margin: 31%, trailing twelve months to Q1 2026. EPS: $7.08, trailing twelve months to Q1 2026.

INCYIncyte

HealthcareUSD

$128.15

$78.2052 weeks$129.88

INCY as reported

Incyte reported $5.36B of revenue over the trailing twelve months, +21% on the year before. 10 reported series are charted on this page, each one as filed.

$5.36B

Revenue, trailing twelve months · to Q1 2026 · +21% against the twelve months before

Net Income: $1.43B
Net Income · +6631% year on year · trailing twelve months to Q1 2026
Op Margin: 31%
Op Margin · trailing twelve months to Q1 2026
EPS: $7.08
EPS · +2732% year on year · trailing twelve months to Q1 2026

Every series Ryufin has for INCY, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$5.36B	+21%	Q1 2026
Net Income	$1.43B	+6631%	Q1 2026
EPS	$7.08	+2732%	Q1 2026
Gross Margin	93%	n/a	Q1 2026
Op Margin	31%	n/a	Q1 2026
Net Margin	27%	n/a	Q1 2026
ROE	24%	n/a	Q1 2026
ROA	18%	n/a	Q1 2026
Free Cash Flow	$892M	n/a	Q4 2022 · 13 quarters behind
P/E	18.1	n/a	today